Jco precision oncology.

DOI: 10.1200/PO.18.00414 JCO Precision Oncology no. 4 (2020) 557-569. Published online June 1, 2020. PMID: 32923885. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients Jingyu Cao, MD 1. x. Jingyu Cao. Search for articles by this author; Jing ...The increased affordability, accessibility, and reliability of DNA and RNA high-throughput sequencing platforms and bioinformatics capabilities enable oncologists to provide more personalized care, often referred to as precision oncology. 1 However, the accelerated development and diffusion of new commercial and noncommercial tumor gene sequencing panels have made this a challenging time for ...Looking for TASHKENT CITY ONCOLOGICAL DISPENSER. in Tashkent? - ☎️Phones ⚑Location of the company on the map, search for directions, how to get …DOI: 10.1200/PO.22.00342 JCO Precision Oncology no. 7 (2023) e2200342. Published online January 12, 2023. PMID: 36634297 Programmatic …This confidence in precision oncology in the absence of definitive RCTs has resulted in creative RWE solutions to the marketplace demand (eg, TAPUR [Targeted Agent and Profiling Utilization Registry] …

DOI: 10.1200/PO.20.00321 JCO Precision Oncology no. 5 (2021) 510-524. Published online March 19, 2021. Published online March 19, 2021. Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based TherapyWeb

JCO PO publishes controlled randomized clinical trials and other comparative studies in precision oncology. For randomized clinical trials and other comparative studies, authors should carefully follow the ICMJE and CONSORT statement guidelines. To produce consistent results, please refer to JCO PO 's CONSORT template.

DOI: 10.1200/PO.19.00172 JCO Precision Oncology - published online September 20, 2019 PMID: 32923866. Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia Roberta La Starza, MD, PhD 1. x. Roberta La Starza. Search for articles by this author ...DOI: 10.1200/PO.21.00267 JCO Precision Oncology no. 6 (2022) e2100267. Published online February 2, 2022. PMID: 35108036. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers Benjamin Garmezy, MD 1. x ...Mar 9, 2022 · PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS We searched the ... DOI: 10.1200/PO.21.00245 JCO Precision Oncology no. 6 (2022) e2100245. Published online March 23, 2022. PMID: 35319967. Landscape of KRAS G12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers Mohamed E. Salem, MD 1. x ...WebDOI: 10.1200/PO.21.00101 JCO Precision Oncology no. 5 (2021) 1166-1177. Published online July 21, 2021. Published online July 21, 2021. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases

DOI: 10.1200/PO.22.00517 JCO Precision Oncology no. 6 (2022) e2200517. Published online November 12, 2022. PMID: 36370464. Multigene Panel Testing Yields High Rates of Clinically Actionable Variants Among Patients With Colorectal Cancer Sarah E. Coughlin, MD 1. x. Sarah E. Coughlin. Search for articles by this author ...

Jun 1, 2023 · Diagnosis & treatment of ercc3-mutant cancer US20210137850A1. Other Relationship: AnaNeo Therapeutics. Jinru Shia. Consulting or Advisory Role: PAIGE.AI. Zsofia K. Stadler. This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript.

JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of …DOI: 10.1200/PO.23.00092 JCO Precision Oncology no. 7 (2023) e2300092. Published online July 6, 2023. PMID: 37410975. Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness ...Standardizing Brain Magnetic Resonance Imaging using Generative Adversarial Networks: A Multisite Study Approach. Kulkarni, Chaitanya; Dinesh, M. S.; Dekker, Andre; More. …DOI: 10.1200/PO.20.00436 JCO Precision Oncology no. 5 (2021) 744-750. Published online May 3, 2021. Published online May 3, 2021. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression—A Case ReportDOI: 10.1200/PO.20.00008 JCO Precision Oncology no. 4 (2020) 393-410. Published online April 23, 2020. PMID: 35050740. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non–Small-Cell Lung Cancer With Rare or Complex Mutational Profiles ...The introduction of NGS assays has allowed the cancer genome to be systematically studied, providing oncologists with more comprehensive, precise, predictive, prognostic, and diagnostic information. 2 NGS-based gene panel tests have successfully identified driver mutations in lung cancers, 3,4 colorectal cancer, 5 and breast cancer, 3 which in turn has resulted in the development and use of ...Given the high attrition rate of de novo drug discovery and limited efficacy of single-agent therapies in cancer treatment, combination therapy prediction through in silico drug repurposing has risen as a time- and cost-effective alternative for identifying novel and potentially efficacious therapies for cancer. The purpose of this review is to provide an introduction to computational methods ...

Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy.JCO Precision Oncology (JCO PO) is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer.Patient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy.This confidence in precision oncology in the absence of definitive RCTs has resulted in creative RWE solutions to the marketplace demand (eg, TAPUR [Targeted Agent and Profiling Utilization Registry] …DOI: 10.1200/PO.21.00510 JCO Precision Oncology no. 6 (2022) e2100510. Published online June 8, 2022. PMID: 35675577. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures Kabir Mody, MD 1. x. Kabir Mody. Search for articles by this author; ...WebJCO PO is a peer-reviewed, online-only, article-based journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer. Innovative and timely scientific and educational content provide a deeper ...WebDOI: 10.1200/PO.19.00333 JCO Precision Oncology no. 4 (2020) 411-425. Published online April 23, 2020. PMID: 35050738. Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review Jing Zhao, MD 1. x. Jing Zhao. Search for articles by this author. and Yang ...Web

May 11, 2022 · DOI: 10.1200/PO.21.00535 JCO Precision Oncology no. 6 (2022) e2100535. Published online May 11, 2022. PMID: 35544728

PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we analyzed the implementation of a multidisciplinary PMed program ...DOI: 10.1200/PO.22.00363 JCO Precision Oncology no. 7 (2023) e2200363. Published online May 24, 2023. PMID: 37224427. Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma ...DOI: 10.1200/PO.21.00463 JCO Precision Oncology no. 6 (2022) e2100463. Published online April 27, 2022. Published online April 27, 2022. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast …PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that ctDNA testing could have on the conduct of clinical trials. METHODS We searched the ...JCO Precision Oncology ( JCO PO) is a peer-reviewed, online-only journal publishing original research, reports, opinions, and reviews that advance the science and practice of precision oncology and define genomics- and other biomarker-driven clinical care of patients with cancer.DOI: 10.1200/PO.20.00472 JCO Precision Oncology no. 5 (2021) 1312-1324. Published online August 19, 2021. Published online August 19, 2021. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor SamplesPatient-level clinical and ctDNA data were pooled and harmonized from 200 patients across five independent clinical trials investigating the treatment of patients with non–small-cell lung cancer with programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1)–directed monotherapy or in combination with chemotherapy.

Journal of Clinical Oncology JCO Oncology Practice JCO Global Oncology JCO Clinical Cancer Informatics JCO Precision Oncology. Publications. ASCO Educational Book ASCO Daily News ASCO Connection The ASCO Post

This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: TP Therapeutics, Nuvalent, Inc. Honoraria: Natera.

Alberta Precision Labs (APL) is a medical laboratory that offers a wide range of diagnostic tests and services. If you need to book an appointment with APL, there are a few things you should know before you go.DOI: 10.1200/PO.21.00181 JCO Precision Oncology no. 6 (2022) e2100181. Published online March 9, 2022. PMID: 35263168. Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors Pashtoon M. Kasi, MD, MS 1. x. Pashtoon M. Kasi. Search for articles by …WebPrecision fabrication is a critical process in various industries, including manufacturing, construction, and automotive. Whether it’s building structures, creating intricate metal designs, or repairing equipment, welding plays a crucial ro...Ian F Tannock's Comment1 summarises the experience to date in precision medicine for children with cancer2–4 and its parallel with the adult experience. The …JCO Precision Oncology 10.1200/PO.17.00071 (2017). Google Scholar. Yoshida, G.J. Applications of patient-derived tumor xenograft models and tumor organoids ...DOI: 10.1200/PO.20.00516 JCO Precision Oncology no. 5 (2021) 653-663. Published online April 13, 2021. Published online April 13, 2021. MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and …WebAs such, scientific outlets in general, and JCO Precision Oncology in particular, owe an immense debt of gratitude to our volunteer peer reviewers. JCO PO strives to provide the highest quality peer review, so in recognition of Peer Review Week 2023 and its theme of Peer Review and The Future of Publishing, ...PURPOSE The adoption of precision medicine (PMed) depends on the critical curation of data and interpretation of genomic results. Herein, we sought to study the effect of a coordinated multidisciplinary program to assess results in a community cancer center clinic. METHODS In a retrospective review from July 2018 to July 2021, we analyzed the implementation of a multidisciplinary PMed program ...Jan 8, 2021 · DOI: 10.1200/PO.20.00178 JCO Precision Oncology no. 5 (2021) 44-50. Published online January 8, 2021. Published online January 8, 2021. Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations DOI: 10.1200/PO.22.00342 JCO Precision Oncology no. 7 (2023) e2200342. Published online January 12, 2023. PMID: 36634297 Programmatic …DOI: 10.1200/PO.19.00116 JCO Precision Oncology - published online August 29, 2019WebDOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study Tareq Al Baghdadi, MD 1. x. Tareq Al Baghdadi. Search for articles by this author ...Web

DOI: 10.1200/PO.22.00107 JCO Precision Oncology no. 6 (2022) e2200107. Published online August 17, 2022. PMID: 35977349. Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors Matthew Dankner, BSc 1, 2, 3. x. Matthew Dankner. Search for articles by this …DOI: 10.1200/PO.20.00504 JCO Precision Oncology no. 6 (2022) e2000504. Published online January 27, 2022. PMID: 35085008. Improved Gene Fusion Detection in Childhood Cancer Diagnostics Using RNA Sequencing Jayne Y. Hehir-Kwa, PhD 1. x. Jayne Y. Hehir-Kwa. Search for articles by this author ...The analysis focuses on the independent and cumulative impacts of gaps occurring during seven steps of the precision oncology pathway, from diagnosis to treatment. Results: For every 1,000 patients in the study cohort, 497 (49.7%) are lost to precision oncology because of factors associated with getting biomarker test results. Among the 503 of ...WebThis author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …Instagram:https://instagram. sealed air corporation stockwaltons walmarthow to analyze a stockten best stocks under dollar10 This author is a member of the JCO Precision Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Employment: Foundation Medicine. Stock and Other Ownership Interests: Roche. Hanna Tukachinsky. Employment: Foundation Medicine. Stock and Other Ownership Interests: …Jul 19, 2023 · In this prospective, case-control study, we assessed the performance of a blood-based multi-cancer detection test to detect cancer and predict the origin of the cancer signal in individuals with symptoms suspicious for cancer. how much is 1979 silver dollar worthcloud computing etf DOI: 10.1200/PO.21.00484 JCO Precision Oncology no. 6 (2022) e2100484. Published online October 31, 2022. PMID: 36315916. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology ...Web datadog price Aug 14, 2019 · DOI: 10.1200/PO.19.00124 JCO Precision Oncology - published online August 14, 2019 Acknowledgment of Reviewers, 2023. Peer review is at the core of scientific progress. It is through the careful critique of peer reviewers that manuscripts are scrutinized, evaluated, and improved. An article that has been peer reviewed is determined to be valid and worthy of publication. These peer-reviewed manuscripts are a critical component ...